Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Orvepitant Maleate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Columbus Venture Partners
Deal Size : $27.8 million
Deal Type : Series B Financing
NeRRe Therapeutics Raises £20 Million in a Series B2 Financing Round
Details : New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis (IPF). The chronic cough can markedly reduce quality of life, is often refractory to medical therapy and there are no approved t...
Product Name : GW823296X
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 07, 2021
Lead Product(s) : Orvepitant Maleate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Columbus Venture Partners
Deal Size : $27.8 million
Deal Type : Series B Financing
Reset All
